Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ensemble and Alexion Initiate Collaboration

Published: Friday, July 26, 2013
Last Updated: Friday, July 26, 2013
Bookmark and Share
Goal of discovering small molecule drug candidates for worldwide development and commercialization by Alexion.

Ensemble Therapeutics has announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.

The collaboration will deploy Ensemble’s proprietary drug discovery platforms for several undisclosed drug targets identified by Alexion to create highly innovative small molecule therapeutic candidates.

Under the terms of the collaboration, Ensemble will screen its Ensemblin™ collection of more than ten million macrocycles against several disease drug targets specified by Alexion, utilizing Ensemble’s extensive medicinal chemistry capabilities to discover new small molecule clinical candidates.

Alexion will have the exclusive worldwide rights to develop and commercialize candidates arising from the collaboration. Other terms of the agreement were not disclosed; Ensemble will receive an upfront payment and research support, and can earn additional payments upon the achievement of certain development and commercial milestones.

“Ensemble is thrilled to support Alexion’s cutting edge scientific and clinical programs with our ever increasing capability for macrocycle-based drug discovery,” said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics.

“This new collaboration with a leading biopharmaceutical innovator focused on rare diseases speaks to the breadth of utility of Ensemble’s discovery platforms to address clinically important yet challenging drug targets,” Dr. Taylor added.

“Alexion looks forward to a productive collaboration with Ensemble as we seek to broaden the number of pathways toward developing potentially transformative first-in-class drug candidates for patients with selected severe and life-threatening ultra-rare disorders,” said Martin Mackay, PhD, Executive Vice President, Head of Global R&D at Alexion. “This is a promising addition to our development initiatives as we seek to further expand our product portfolio.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Unique Visual Stimulation May Be New Treatment for Alzheimer’s
Noninvasive technique reduces beta amyloid plaques in mouse models of Alzheimer’s disease.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!